II. AMENDMENTS TO THE CLAIMS

The below listing of claims will replace all prior versions, and listings, of claims in the present application:

1-25. (Cancelled)

26. (Currently Amended) A method of treating cancer which comprises administering to a subject in need of treatment a therapeutically effective amount of a ruthenium(II) compound of formula (I):



(I)

wherein:

R^1, R^2, R^3, R^4, R^5 and R^6 independently represent H, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, halo, CO_2R^7, $CONR^8R^9$, COR^{10}, SO_3H, $SO_2NR^{11}R^{12}$, aryloxy, (C_1-C_6)alkoxy, (C_1- C_6)alkylthio, -N=N-R^{13}, $NR^{14}R^{15}$, aryl or aralkyl, which latter two groups are optionally substituted on the aromatic ring by one or more groups independently selected from (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, aryl, aralkyl, halo, CO_2R^{7a}, $CONR^{8a}R^{9a}$, COR^{10a}, SO_3G, $SO_2NR^{11a}R^{12a}$, aryloxy, (C_1-C_6)alkoxy, (C_1- C_6)alkylthio, -N=N-R^{13a}, $NR^{14a}R^{15a}$, or R^1 and R^2 together with the ring to which they are bound represent a saturated or unsaturated carbocyclic or heterocyclic group containing up to three 3-to 8-membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings, and wherein each of the rings

may be optionally substituted by one or more groups independently selected from $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$, aryloxy, $(C_1$-$C_6)$alkylthio, $-N=N-R^{13b}$, $NR^{14b}R^{15b}$ or $(C_1$-$C_6)$alkoxy;

R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{7a}, R^{8a}, R^{9a}, R^{10a}, R^{11a}, R^{12a}, R^{13a}, R^{14a}, R^{15a}, R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are independently selected from H, $(C_1$-$C_6)$alkyl, aryl or aralkyl;

X is a neutral or negatively charged O-, N- or S-donor ligand or halo;

G and G' are independently selected from alkali metals, aryl, aralkyl and $(C_1$-$C_6)$ alkyl;

Y-L-Y' is a bidentate ligand bearing negative charge with a proportion of the charge on both Y and Y', ~~Y and Y' are independently selected from O, S or NR^{16}; wherein R^{16} is H, $(C_1$-$C_6)$ alkyl, aryl or aralkyl, and L is a group linking Y and Y' and comprises one or more groups selected from $(C_1$-$C_6)$ alkylene, $(C_1$-$C_6)$ alkenylene, $(C_1$-$C_6)$ alkynylene, arylene, aralkylene, alkarylene, each of said latter six groups being optionally substituted, ferrocenylene, Se, Se-Se, S-S, N=N and C=O;~~ wherein Y-L-Y' is selected from the ligands of formulas (II) and (III):



(II)



(III)

wherein T, T', T'' and T''' are O;

R_{1c} to R_{3c} are independently H, $(C_1$-$C_6)$alkyl, aryl, aralkyl, wherein the latter two groups are optionally substituted by one or more groups independently selected from $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$, aryloxy, $(C_1$-$C_6)$alkylthio, $-N=N-R^{13b}$, $NR^{14b}R^{15b}$ or $(C_1$-$C_6)$alkoxy, wherein R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are as defined;

and R_{1h} to R_{4h} are independently H, $(C_1$-$C_6)$alkyl, aryl, aralkyl, wherein the latter two groups are optionally substituted by one or more groups independently selected from $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$, aryloxy, $(C_1$-$C_6)$alkylthio, $-N=N-R^{13b}$, $NR^{14b}R^{15b}$ or $(C_1$-$C_6)$alkoxy, wherein R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are as defined;

m is -1, 0 or +1 and the compound comprises a counterion when m is -1 or +1;

the compound of formula (I) optionally being in the form of a dimer in which two L groups are linked either directly or through a group comprising one or more of $(C_1$-$C_6)$ alkylene, $(C_1$-$C_6)$ alkenylene, arylene, aralkylene, alkarylene, Se, Se-Se, S-S, N=N and C=O or in which L bears two Y groups and two Y' groups.

27. (Previously Presented) The method as claimed in claim 26, wherein R^1, R^2, R^3, R^4, R^5 and R^6 are independently selected from H, $(C_1$-$C_6)$ alkyl and phenyl or R^1 and R^2 together with the ring to which they are bound represent anthracene or a hydrogenated derivative of anthracene, said phenyl and anthracene or a hydrogenated derivative of anthracene group being optionally substituted by one or more groups independently selected from $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$ alkenyl, $(C_2$-$C_6)$alkynyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$alkyl, phenyl, benzyl, halo,

carboxyl, $CO_2(C_1\text{-}C_6)$alkyl, $CONH_2$, COH, $CO(C_1\text{-}C_6)$alkyl, SO_3H, SO_2NH_2, phenoxy, $(C_1\text{-}C_6)$alkylthio, NH_2 or $(C_1\text{-}C_6)$ alkoxy.

28. (Previously Presented) The method as claimed in claim 26, wherein m is 0.

29. (Previously Presented) The method as claimed in claim 26, wherein X is halo or CH_3CN.

30. (Currently Amended) The method as claimed in claim 26, wherein Y-L-Y' ~~is selected from~~ comprises the ligand[[s]] of formula[[e]] (II) ~~to (VI) and (VIII) to (X)~~:



(II)



~~(III)~~



~~(IV)~~



~~(V)~~



~~(VI)~~



~~(VIII)~~



~~(IX)~~



~~(X)~~

31. (Currently Amended) The method as claimed in claim 26, wherein Y-L-Y' ligand comprises formula (III) ~~is selected from~~:



(III)



~~(XI)~~



~~(XII)~~



~~(XIII)~~



~~(XIV)~~



~~(XV)~~

~~wherein T, T', T'' and T''' are independently selected from O and S,~~

~~A comprises one or more groups selected from (C_1-C_6)alkylene, (C_1-C_6)alkenylene, (C_1-C_6) alkynylene, arylene, aralkylene, alkarylene, ferrocenylene, Se, Se-Se, S-S, N=N and C=O;~~

~~and R_{1i} to R_{6j} are independently H, (C_1-C_6)alkyl, aryl, aralkyl, wherein the latter two groups are optionally substituted by one or more groups independently selected from (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$, aryloxy, (C_1-C_6)alkylthio, $N=N-R^{13b}$, $NR^{14b}R^{15b}$ or (C_1-C_6)alkoxy, wherein R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are as defined.~~

32. (Currently Amended) The method as claimed in claim 26, wherein Y-L-Y' is:



wherein T and T' are ~~independently O and S~~, and R, R_{1c}, and R_{3c} are independently H, (C_1-C_6)alkyl, aryl, aralkyl, wherein the latter two groups are optionally substituted by one or more groups independently selected from (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$, aryloxy, (C_1-C_6)alkylthio, $-N=N-R^{13b}$, $NR^{14b}R^{15b}$ or (C_1-C_6)alkoxy, wherein R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are as defined.

33. (Previously Amended) The method as claimed in claim 32, wherein T and T' are both O, R is H or $(C_1$-$C_6)$ alkyl and R_{1c} and R_{3c} are independently $(C_1$-$C_6)$alkyl or phenyl, said phenyl optionally substituted by $(C_1$-$C_6)$alkyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$ alkyl, halo, carboxyl, $CO_2(C_1$-$C_6)$alkyl, $CONH_2$, COH, $CO(C_1$-$C_6)$alkyl, SO_3H, SO_2NH_2, phenoxy, $(C_1$-$C_6)$ alkylthio, NH_2 or $(C_1$-$C_6)$alkoxy.

34. (Previously Amended) The method as claimed in claim 33, wherein R is H and R_{1c} and R_{3c} are independently $(C_1$-$C_6)$alkyl or phenyl.

35. (Cancelled)

36. (Currently Amended) A method of treating ovarian adenocarcinoma which comprises administering to a subject in need of treatment a therapeutically effective amount of a ruthenium(II) compound of formula (I):



(I)

wherein:

R^1, R^2, R^3, R^4, R^5 and R^6 independently represent H, $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$alkyl, halo, CO_2R^7, $CONR^8R^9$, COR^{10}, SO_3H, $SO_2NR^{11}R^{12}$, aryloxy, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$alkylthio, $-N=N-R^{13}$,

$NR^{14}R^{15}$, aryl or aralkyl, which latter two groups are optionally substituted on the aromatic ring by one or more groups independently selected from $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$alkyl, aryl, aralkyl, halo, CO_2R^{7a}, $CONR^{8a}R^{9a}$, COR^{10a}, SO_3G, $SO_2NR^{11a}R^{12a}$, aryloxy, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$alkylthio, $-N=N-R^{13a}$, $NR^{14a}R^{15a}$, or R^1 and R^2 together with the ring to which they are bound represent a saturated or unsaturated carbocyclic or heterocyclic group containing up to three 3-to 8-membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings, and wherein each of the rings may be optionally substituted by one or more groups independently selected from $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$, aryloxy, $(C_1$-$C_6)$alkylthio, $-N=N-R^{13b}$, $NR^{14b}R^{15b}$ or $(C_1$-$C_6)$alkoxy;

R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{7a}, R^{8a}, R^{9a}, R^{10a}, R^{11a}, R^{12a}, R^{13a}, R^{14a}, R^{15a}, R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are independently selected from H, $(C_1$-$C_6)$alkyl, aryl or aralkyl;

X is a neutral or negatively charged O-, N- or S-donor ligand or halo;

G and G' are independently selected from alkali metals, aryl, aralkyl and $(C_1$-$C_6)$ alkyl;

Y-L-Y' is a bidentate ligand bearing negative charge with a proportion of the charge on both Y and Y', ~~Y and Y' are independently selected from O, S or NR^{16}, wherein R^{16} is H, $(C_1$-$C_6)$ alkyl, aryl or aralkyl, and L is a group linking Y and Y' and comprises one or more groups selected from $(C_1$-$C_6)$ alkylene, $(C_1$-$C_6)$ alkenylene, $(C_1$-$C_6)$ alkynylene, arylene, aralkylene, alkarylene, each of said latter six groups being optionally substituted, ferrocenylene, Se, Se-Se, S-S, N=N and C=O;~~ wherein Y-L-Y' is selected from the ligands of formulas (II) and (III):



(II)



(III)

wherein T, T', T'' and T''' are O;

R_{1c} to R_{3c} are independently H, $(C_1$-$C_6)$alkyl, aryl, aralkyl, wherein the latter two groups are optionally substituted by one or more groups independently selected from $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$, aryloxy, $(C_1$-$C_6)$alkylthio, $-N=N-R^{13b}$, $NR^{14b}R^{15b}$ or $(C_1$-$C_6)$alkoxy, wherein R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are as defined;

and R_{1h} to R_{4h} are independently H, $(C_1$-$C_6)$alkyl, aryl, aralkyl, wherein the latter two groups are optionally substituted by one or more groups independently selected from $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, $(C_2$-$C_6)$alkynyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$, aryloxy, $(C_1$-$C_6)$alkylthio, $-N=N-R^{13b}$, $NR^{14b}R^{15b}$ or $(C_1$-$C_6)$alkoxy, wherein R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are as defined;

m is -1, 0 or +1 and the compound comprises a counterion when m is -1 or +1;

the compound of formula (I) optionally being in the form of a dimer in which two L groups are linked either directly or through a group comprising one or more of

(C_1-C_6) alkylene, (C_1-C_6) alkenylene, arylene, aralkylene, alkarylene, Se, Se-Se, S-S, N=N and C=O or in which L bears two Y groups and two Y' groups.

37. (Previously Presented) The method as claimed in claim 36, wherein R^1, R^2, R^3, R^4, R^5 and R^6 are independently selected from H, (C_1-C_6) alkyl and phenyl or R^1 and R^2 together with the ring to which they are bound represent anthracene or a hydrogenated derivative of anthracene, said phenyl and anthracene or a hydrogenated derivative of anthracene group being optionally substituted by one or more groups independently selected from (C_1-C_6)alkyl, (C_2-C_6) alkenyl, (C_2-C_6)alkynyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, phenyl, benzyl, halo, carboxyl, CO_2(C_1-C_6)alkyl, $CONH_2$, COH, CO(C_1-C_6)alkyl, SO_3H, SO_2NH_2, phenoxy, (C_1-C_6)alkylthio, NH_2 or (C_1-C_6) alkoxy.

38. (Previously Presented) The method as claimed in claim 36, wherein m is 0.

39. (Previously Presented) The method as claimed in claim 36, wherein X is halo or CH_3CN.

40. (Currently Amended) The method as claimed in claim 36, wherein Y-L-Y' ~~is selected from~~ comprises the ligand[[s]] of formula[[e]] (II) ~~to (VI) and (VIII) to (X)~~:



(II)



~~(III)~~



~~(IV)~~



~~(V)~~



~~(VI)~~



~~(VIII)~~



~~(IX)~~



~~(X)~~

~~wherein T and T' are independently selected from O and S,~~

~~R_{1g} and R_{3g} are independently H, (C_1-C_6) alkyl, aryl or aralkyl,~~

~~R_{1e} to R_{3g} R_{5f} and R_{2g} are independently H, (C_1-C_6)alkyl, aryl, aralkyl, wherein the latter two groups and the corresponding groups for R_{1g} and R_{3g} are optionally substituted by one or more groups independently selected from (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$, aryloxy, (C_1-C_6)alkylthio, N=N-R^{13b}, $NR^{14b}R^{15b}$ or (C_1-C_6)alkoxy, wherein R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are as defined.~~

41. (Currently Amended) The method as claimed in claim 36, wherein Y-L-Y' comprises the ligand of formula (III) ~~is selected from~~:



(III)



~~(XI)~~



~~(XII)~~



~~(XIII)~~



~~(XIV)~~



~~(XV)~~

~~wherein T, T', T" and T"' are independently selected from O and S;~~

~~A comprises one or more groups selected from (C_1-C_6)alkylene, (C_1-C_6)alkenylene, (C_1-C_6) alkynylene, arylene, aralkylene, alkarylene, ferrocenylene, Se, Se-Se, S-S, N=N and C=O;~~

~~and R_{1h} to R_{4h} R_{6j} are independently H, (C_1-C_6)alkyl, aryl, aralkyl, wherein the latter two groups are optionally substituted by one or more groups independently selected from (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$, aryloxy, (C_1-C_6)alkylthio, $N=NR^{13b}$, $NR^{14b}R^{15b}$ or (C_1-C_6)alkoxy, wherein R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are as defined.~~

42. (Currently Amended) The method as claimed in claim 36, wherein Y-L-Y' is:



wherein T and T' are ~~independently~~ O ~~and S~~, and R. R_{1c}, and R_{3c} are independently H, (C_1-C_6)alkyl, aryl, aralkyl, wherein the latter two groups are optionally substituted by one or more groups independently selected from (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, aryl, aralkyl, halo, CO_2R^{7b}, $CONR^{8b}R^{9b}$, COR^{10b}, SO_3G', $SO_2NR^{11b}R^{12b}$,

aryloxy, $(C_1$-$C_6)$alkylthio, -N=N-R^{13b}, $NR^{14b}R^{15b}$ or $(C_1$- $C_6)$alkoxy, wherein R^{7b}, R^{8b}, R^{9b}, R^{10b}, R^{11b}, R^{12b}, R^{13b}, R^{14b}, and R^{15b} are as defined.

43. (Currently Amended) The method as claimed in claim 42, wherein T and T' are both O, R is H or $(C_1$-$C_6)$ alkyl and R_{1c} and R_{3c} are independently $(C_1$-$C_6)$alkyl or phenyl, said phenyl optionally substituted by $(C_1$-$C_6)$alkyl, hydroxy$(C_1$-$C_6)$alkyl, amino$(C_1$-$C_6)$ alkyl, halo, carboxyl, $CO_2(C_1$-$C_6)$alkyl, $CONH_2$, COH, $CO(C_1$-$C_6)$alkyl, SO_3H, SO_2NH_2, phenoxy, $(C_1$-$C_6)$ alkylthio, NH_2 or $(C_1$-$C_6)$alkoxy.

44. (Currently Amended) The method as claimed in claim 43, wherein R is H and R_{1c} and R_{3c} are independently $(C_1$-$C_6)$alkyl or phenyl.

45. (Cancelled)